染色体17p^(13.1)位点杂合缺失与乳腺癌生物学行为及预后的关系  

Loss of Heterozygosity on Chromosome 17p^(13.1) and Biologic Behavior and Prognosis of Human Breast Cancer

作　　者：王洪义[1] 崔建涛[1] 吕有勇[1] 

机构地区：[1]北京大学临床肿瘤学院,北京市肿瘤防治研究所,100036

出　　处：《实用癌症杂志》2001年第4期357-359,共3页The Practical Journal of Cancer

摘　　要：目的　探讨染色体 17p13 .1位点杂合缺失 (LOH )与乳腺癌生物学行为及预后的关系。方法　应用PCR 限制性片段长度多态性分析 (PCR RFLP)的方法 ,检测 60例原发性乳腺癌患者 17号染色体短臂 17p13 .1位点LOH。结果　经PCR扩增、酶切和电泳分离 ,在 17p13 .1位点共筛选出信息个体 3 8例 ,LOH发生频率为 42 .1% (16/3 8)。在Ⅰ～Ⅱ期和Ⅲ～Ⅳ期乳癌中LOH阳性率分别为 5 6.0 %和 15 .4% ,有显著性差异 (P <0 .0 5 )。而该位点LOH与淋巴结转移及ER、PR水平无明显相关。分析 17p13 .1位点LOH与预后的关系发现 ,LOH阳性乳腺癌患者术后生存期明显较LOH阴性患者短 (P <0 .0 1)。结论　 17p13 .1位点LOH多发生在乳腺癌病变早期 ,检测该位点LOH有可能成为判断乳腺癌预后的 1个新的分子生物学指标。Objective To study the association of loss of heterozygosity(LOH) on chromosome 17p 13.1 with biologic behavior and prognosis of human breast cancer.Methods The LOH at 17p 13.1 was measured in 60 patients with breast cancer by polymerase chain reaction(PCR)-restriction fragment length polymorphisms(RFLP).Results The informative cases were found in 38 of 60 breast cancer patients.LOH on the 17p 13.1 locus was revealed in 42.1%(16/38) of informative cases.The frequency of LOH at this site was higher in stage Ⅰ～Ⅱ breast cancer patients(56.0%) than those in stage Ⅲ～Ⅳ(15.4%)(P<0.05).LOH was not correlated with axillary lymph node involvement and oestrogen or progesterone receptor status.However,the presence of 17p 13.1 deletion was associated with a shortened survival in all patients(P<0.01,by Log-Rank test).Conclusion This observation indicates that 17p 13.1 deletion seems to develop in earlier stage of breast tumorigenesis and it will probably be a useful prognostic indicator in patients with breast cancer.

关 键 词：乳腺癌 17p杂合缺失 预后 生物学行为 

分 类 号：R737.9[医药卫生—肿瘤]